CHEST Clinical Trials Opportunities

AstraZeneca announced the initiation of two new phase III clinical trials investigating the potential of their fixed-dose triple combination inhaled therapy to address cardiopulmonary risk and improve outcomes in people living with COPD.

THARROS is the first-ever prospective phase III trial investigating the potential effect of our triple therapy on severe cardiopulmonary outcomes in people with COPD who also have elevated cardiopulmonary risk, irrespective of exacerbation history. If positive, THARROS will provide critical evidence that could advance treatment goals in COPD.

ATHLOS is another new phase III trial investigating our triple therapy vs inhaled corticosteroid/long-acting β₂-agonist budesonide/formoterol fumarate or placebo on cardiopulmonary parameters including hyperinflation and exercise endurance time, which are associated with health status and survival.

These trials support AstraZeneca's ambition to transform care for people with COPD by expanding the scientific understanding of COPD, its connection to cardiopulmonary risk, and the potential impact of triple therapy on outcomes. To learn more about these trials, please view the press release. You can also find the clinicaltrials.gov links for both trials (which are actively recruiting) below for you to list on your website as you see fit:

THARROS »

ATHLOS »

Sanofi and Regeneron are studying the long-term effect of dupilumab on the prevention of lung function decline in adult patients with uncontrolled moderate to severe asthma. This phase 3b/4 study (ATLAS) is an interventional, randomized, parallel group, treatment, double-blind, two-arm study to assess the effect of dupilumab compared with standard-of-care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma.

The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double-blinded treatment period. There will be a post-treatment follow-up period up to 12 weeks.

A number of clinical trial sites are available and recruiting patients across the United States. For additional information, or to learn if you might be eligible, please visit Sanofi Studies or ClinicalTrials.gov.

Boehringer Ingelheim is conducting a phase 3 clinical trial in adults 18 years of age or older who are diagnosed with interstitial lung disease (ILD) with progressive pulmonary fibrosis. If they already take nintedanib for their ILD, they can continue treatment throughout the study. The FIBRONEER™-ILD study aims to evaluate the safety and effectiveness of an oral investigational drug, BI 1015550 (a phosphodiesterase 4B inhibitor), when compared with a placebo. Approximately 1,040 participants will take part in the ILD study, which involves around 400 study centers worldwide. This trial is currently enrolling participants. Participants who complete FIBRONEER-ILD will be offered the chance to participate in the long-term open-label extension study, FIBRONEER-ON. For more information on the study eligibility criteria and trial sites, please visit ClinicalTrials.gov (NCT05321082). https://classic.clinicaltrials.gov/ct2/show/NCT05321082

Contact information: Boehringer Ingelheim, +1 (800) 243-0127 or clintriage.rdg@boehringer-ingelheim.com

Boehringer Ingelheim is recruiting patients who have pulmonary fibrosis and cough for a trial. This is an observational study (a study drug is not being tested) to measure the burden of cough in patients with pulmonary fibrosis. The study involves the use of digital technology (Strados Remote Electronic Stethoscope) to measure cough.

ClinicalTrials.gov ID: NCT05670587

Sites are located throughout the US. Please contact +1 (833) 602-2368 or unitedstates@bitrialsupport.com.